Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OSR Holdings ( (OSRH) ) has shared an announcement.
On January 13, 2025, Vaximm AG, a wholly owned subsidiary of OSR Holdings, entered into a binding term sheet with BCM Europe AG, OSR’s largest shareholder, for a proposed global exclusive license of Vaximm’s lead oral cancer immunotherapy platform VXM01, replacing a prior non-binding proposal from November 21, 2025. Under the binding economic terms, once a definitive agreement is signed, a BCM-managed investment vehicle would receive global exclusive rights to develop and commercialize VXM01 in exchange for a $30 million upfront payment split between cash and digital assets and up to $815 million in predominantly clinical and development milestones, alongside a royalty pass-through structure tied to any future ultimate commercial licensee; Vaximm’s board has initiated a comprehensive review and will obtain an independent third-party fairness opinion to assess financial fairness for Vaximm and OSR shareholders, signaling a potentially transformative monetization of VXM01 that could materially bolster OSR’s funding for later-stage development while preserving long-term upside and reinforcing its positioning in the immuno-oncology space, even as final completion remains contingent on customary approvals and execution of a definitive licensing agreement.
More about OSR Holdings
OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company focused on advancing biomedical innovations across immuno-oncology, regenerative biologics and medical device technologies through its subsidiaries, including Swiss-German biotech unit Vaximm AG, whose orally administered T‑cell vaccination platform uses live, attenuated bacterial vectors to deliver tumor-associated antigens, with lead cancer immunotherapy candidate VXM01 targeting VEGFR-2 and having shown clinical activity and safety in multiple indications.
Average Trading Volume: 5,482,691
Technical Sentiment Signal: Sell
Current Market Cap: $18.4M
For a thorough assessment of OSRH stock, go to TipRanks’ Stock Analysis page.